With its lead gene therapy nearing the clinic, SwanBio leans heavily on Syncona to close $56M series B

Syncona is continuing to bet big on gene therapy. While setbacks at other biotechs have taken the sheen off the modality, the investor is keeping the faith in SwanBio Therapeutics, stepping up to provide the lion’s share of a $56 million series B round that will support an early-phase clinical trial.